Results 161 to 170 of about 53,280 (246)

Tofacitinib combined with fire needle therapy for refractory cutaneous Rosai-Dorfman disease: a first case report and literature review. [PDF]

Front Med (Lausanne)
Zhang Y, Zheng P, Hu B, Chen L.
europepmc   +1 more source

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update [PDF]

, 2014
Aletaha, D. (Daniel), Betteridge, N. (Neil), Bijlsma, J.W.J. (Hans), Boers, M. (Maarten), Breedveld, F.C. (Ferdinand), Buch, T. (Thorsten), Burmester, G.R. (Gerd), Buttgereit, F. (Frank), Combe, B. (Bernard), Cutolo, M. (Maurizio), Damjanov, N. (Nemanja), Dougados, M. (Maxime), Emery, P. (Paul), Gaujoux-Viala, C. (Cécile), Gossec, L. (Laure), Hazes, J.M.W. (Mieke), Heijde, D. (Desiree) van der, Kouloumas, M. (Marios), Kvien, T.K. (Tore), Landewé, R.B.M. (Robert), M. de Wit (Maarten), Mariette, X. (Xavier), Nam, N. (Nguyen) van, Pavelka, K. (Karel), Ramiro, S. (Sofia), Riel, P.L.C.M. (Piet) van, Rubbert-Roth, A. (Andrea), Scholte-Voshaar, M. (Marieke), Scott, D.L. (David), Smolen, J.S. (Josef), Sokka-Isler, T. (Tuulikki), Winthrop, K. (Kevin), Wong, J.B. (John)   +32 more
core   +1 more source

XIAP Deficiency Impairs Colonic Tuft Cell Development and Predisposes to Crohn's Disease

MedComm, Volume 7, Issue 5, May 2026.
XIAP deficiency leads to impaired colonic tuft cells development and JAK–‐STAT pathway hyperactivation in CD patients and mice. Mechanically, XIAP regulates tuft cells development through Wnt–‐TLE4/TCF–‐ASCL2 signaling. Tuft cells deficiency predisposes XIAP‑‐deficient CD patients or Xiap−/−‐/‐ mice to hazardous microbial effects, driving colonic ...
Rongli Fang, Wei Wang, Li Zhang, Jiwei Huang, Lei Huang, Huibo Wu, Yuyin Qi, Lili Li, Liren Tan, Min Zhang, Jianheng Zhu, Xiang Peng, Kanghua Zhong, Ming Zou, Xi Yang, Qiuhua Wang, Changjun Nie, Chaorui Tang, Ning Tang, Lanlan Geng, Hanhan Chen, James E. Vince, Hirokazu Kanegane, Xiaodong Zhao, Huifang Xian, Wenhao Zhou, Min Zhi, Yuxia Zhang, Zhanghua Chen   +28 more
wiley   +1 more source

Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature. [PDF]

Health Sci Rep
Ansari MS, Heidari S, Pourgholi E, Bahramian S, Tootoonchi N, Vahabi SM.   +5 more
europepmc   +1 more source

Tofacitinib in active ulcerative colitis [PDF]

, 2012
COTTONE, Mario, Orlando A, Papi C.
core   +1 more source

MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Model‐based meta‐analysis (MBMA) offers a powerful framework for quantitatively integrating clinical trial data to inform drug development and decision‐making. In this study, a novel quantitative modeling approach using MBMA was proposed to project key efficacies of treatment in future Phase 2 or Phase 3 studies for an untested indication.
Mehrdad Javidi, Gregory E. Alexander, Teddy Kosoglou, An Vermeulen, Anna Beutler, Tasneam Shagroni, Chandni Valiathan   +6 more
wiley   +1 more source

A Rationally Designed Novel Bifunctional Human TNF-α- and Janus Kinase-Targeted soloMER Drug Conjugate (SDC) with a Neutrophil Elastase Cleavable Linker Delivering Inflammation Site-Specific Release of Payload. [PDF]

J Med Chem
Murray E, Priyanka S, Martinez-Fraile J, Grygorash R, Idress M, Brownbridge LC, Glavina S, Camper N, Boyd R, Porter AJ, Barelle CJ, Ubah OC.   +11 more
europepmc   +1 more source

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF.
Ailsa Hart, Seyedehsan Navabi, Geert D'Haens, Katsuyoshi Matsuoka, María Dolores Martín‐Arranz, Raja Atreya, Karen Hamrick Samaan, Endip Dhesi, Isabel Redondo, Baojin Zhu, Jerome Paulissen, Liliana Zaremba‐Pechmann, Simin Baygani, Jimmy Limdi, David Laharie, Silvio Danese   +15 more
wiley   +1 more source

Case Report: Successful treatment of steroid-refractory immune checkpoint inhibitor associated myocarditis with tofacitinib. [PDF]

Front Immunol
Kong D, Zhang F, Liu Y, Zhu X, Yuan T, Liu A, Zhou L, Chen W, Yao Q.   +8 more
europepmc   +1 more source

Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction

The Journal of Dermatology, Volume 53, Issue 5, Page 746-757, May 2026.
ABSTRACT Baricitinib and ritlecitinib are newly approved systemic Janus kinase (JAK) inhibitors for severe, refractory alopecia areata (AA). Although clinical trials have demonstrated their efficacy, real‐world evidence remains limited, particularly regarding predictors of response and outcomes following treatment interruption or dose tapering.
Rina Hayashi, Saori Takamura, Tomoo Fukuda   +2 more
wiley   +1 more source